Last reviewed · How we verify
NCT05388409: TRANSVAS
Risk Factors for Portosinusoidal Vascular Disease in Kidney Transplant Recipients:
trial in Porto-Sinusoidal Vascular Disease in 12 participants. Completed in 30 December 2023.
7 February 2023
Quick facts
| Lead sponsor | University Hospital, Caen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 12 |
| Start date | 25 October 2021 |
| Primary completion | 7 February 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across France |
Conditions studied
- Porto-Sinusoidal Vascular Disease — all drugs for Porto-Sinusoidal Vascular Disease →
Sponsor
University Hospital, Caen
Who can join
18 and older, any sex, with Porto-Sinusoidal Vascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To look for the factors of exposure present prior to the onset of Porto-Sinusoidal Vascular Disease (PSVD) and which can lead to the occurrence of PSVD after renal transplantation, and therefore to consider the identification of risk factors, in order to prevent or detect early signs of portal hypertention in predisposed patients and improve their prognosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05388409
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Porto-Sinusoidal Vascular Disease
Currently open trials in the same condition.
- NCT06635122 — TIPS for Platinum-Related Porto-Sinusoidal Vascular Disease With Variceal Bleeding · active not recruiting
Other University Hospital, Caen trials
Trials by the same sponsor.
- NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
- NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
- NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
- NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
- NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05388409 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05388409.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing